The market for ‘gene silencing’ therapies is set to explodeDr Dan WilliamsDec 16, 20241 min readDan Williams discusses the reasons behind the gene silencing explosion in FirstWord Pharma. Read his analysis here.
Dan Williams contributes to a major article for Inside Precision Medicine, in which several US families with a child living with H-ABC discuss their journey to a diagnosis
Dan Williams welcomes news that NICE has raised the cost-effectiveness threshold for ultra-rare disease drugs
Comments